Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Ovid Therapeutics Inc. (OVID)

Ovid Therapeutics warrant exercises bring about $53.9 million in gross proceeds

Neutral Impact 3 of 5 financing Written later

Ovid Therapeutics said Series A Warrants issued in its October 2025 private placement expired on April 17, 2026, and investors exercised them into common shares and pre-funded warrants. The exercises are expected to bring the company gross proceeds of approximately $53.9 million, and the filing notes the new shares and pre-funded warrants will add to the outstanding share count.

Key points

  • Warrants covered 38,481,325 common shares in total, expiring April 17, 2026.
  • Investors exercised into 33,597,860 common shares at $1.40 per share.
  • Investors also exercised into 4,883,464 pre-funded warrants at $1.399 per share, for gross proceeds of approximately $53.9 million.

The filing

CompanyOvid Therapeutics Inc. (OVID)
Form8-K, current report
Filed with the SECApr 20, 2026, 8:16 AM ET
Accession number0001628280-26-025926

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on April 20, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.